Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million Mar 30, 2026
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights Mar 25, 2026
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 Mar 18, 2026
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million Feb 23, 2026
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease Feb 23, 2026
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States Jan 13, 2026
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission Dec 15, 2025
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology Dec 10, 2025
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights Nov 14, 2025
